Amgen and Oxford Genome Sciences (UK) have entered into a strategic collaboration to discover, develop and commercialize novel therapeutic antibodies for the treatment of cancer. This collaboration will enable OGS to  strengthen its pipeline of fully human therapeutic antibodies (mAbs) in cancer based on the target discovery capabilities of its unique OGAP database.

OGS and Amgen will jointly discover novel antibodies for the treatment of cancer. The companies will generate fully human antibodies using Amgen's XenoMouse technology, which was acquired through its acquisition of Abgenix. These antibodies will be raised against the novel druggable targets that OGeS has identified through its unique Oxford Genome Anatomy Project (OGAP) database.

The agreement covers as many as six oncology programs. Amgen will have the right to select as many as three programs, while OGS will retain rights to the remainder. Once Amgen has produced the initial antibody leads, OGeS will carry out the initial preclinical assessment of each antibody program.

News from our sister sites